

Active Targeting of Cancer Cells by Nanobody Decorated Polypeptide Micelle with Bio-orthogonally Conjugated Drug

Simone A. Costa,[†] Davoud Mozhdehi,^{†,‡} Michael J. Dzuricky,[†] Farren J. Isaacs,[‡] Eric M. Brustad,[§] and Ashutosh Chilkoti^{*,†}

[†]Department of Biomedical Engineering, Duke University, Durham, North Carolina 27708, United States


[‡]Department of Molecular, Cellular, and Developmental Biology, Yale University, New Haven, Connecticut 06520, United States

[§]Department of Chemistry, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States

Supporting Information

ABSTRACT: Polypeptides are promising carriers for chemotherapeutics: they have minimal toxicity, can be recombinantly synthesized with precise control over molecular weight, and enhance drug pharmacokinetics as self-assembled nanoparticles. Polypeptide-based systems also provide the ability to achieve active targeting with genetically encoded targeting ligands. While passive targeting promotes accumulation of nanocarriers in solid tumors, active targeting provides an additional layer of tunable control and widens the therapeutic window. However, fusion of most targeting proteins to polypeptide carriers exposes the limitations of this approach: the residues that are used for drug attachment are also promiscuously distributed on protein surfaces. We present here a universal methodology to solve this problem by the site-specific attachment of extrinsic moieties to polypeptide drug delivery systems without cross-reactivity to fused targeting domains. We incorporate an unnatural amino acid, *p*-acetylphenylalanine, to provide a bioorthogonal ketone for attachment of doxorubicin in the presence of reactive amino acids in a nanobody-targeted, elastin-like polypeptide nanoparticle. These nanoparticles exhibit significantly greater cytotoxicity than nontargeted controls in multiple cancer cell lines.

KEYWORDS: Unnatural amino acids, active targeting, cancer drug delivery, polypeptides, self-assembly, nanoparticles



While small molecule drugs are highly potent cytotoxic agents, their poor solubility, short half-life, and insufficient bioavailability often require the use of delivery strategies, such as polymeric nanoscale drug carriers, to improve their delivery to solid tumors.¹ Recent work has demonstrated the importance of three key elements for effective tumor treatment by nanoparticle drug carriers: (1) long circulation time,^{2,3} (2) active targeting,^{4,5} and (3) site-specific attachment of cytotoxic drugs.^{6,7} Long blood circulation is advantageous for regional accumulation in tumors via the enhanced permeability and retention effect, also called passive targeting.⁸ Active targeting of nanoparticles provides the second stage of tumor specific delivery as it enables tumor cell-selective uptake, complementary to the regional accumulation provided by passive targeting, widening the therapeutic window of the drug.⁹ Finally, site-specific conjugation of small molecule drugs to these carriers with tunable chemistries ensures a homogeneous drug carrier population and predictable release.¹⁰

Recombinant peptide polymers are attractive for the design of nanoparticle delivery systems because they can be produced recombinantly in high yield in *E. coli* as monodisperse macromolecules and their sequence and chain length are

easily manipulated at the gene level.^{11,12} They are also nontoxic and biodegradable.¹³ We have pioneered the development of elastin-like polypeptides (ELPs) as a class of peptide polymers that self-assemble into nanoparticles for drug delivery.^{14–16}

ELPs consist of the sequence (VPGXG)_n, where the guest residue X is any amino acid except proline, and *n* is the number of repeats.¹⁷ ELPs are thermally responsive; they phase separate in aqueous solution when heated above their cloud point temperature, also called the inverse transition temperature (*T*_i), and resolubilize completely upon cooling below their *T*_i.¹⁸ Diblock copolymer ELPs, with blocks possessing distinct *T*_is as individual segments, can be designed to self-assemble into nanoscale micelles at physiological temperatures.¹⁹ ELPs can also be fused to other proteins and peptides at their N- or C-termini, or both, without loss of thermal responsivity.²⁰ Self-assembling ELPs have been used as nanoparticle drug carriers to increase the half-life of small molecule drugs for potent tumor regression.^{21–23}

Received: September 21, 2018

Revised: December 4, 2018

Published: December 12, 2018

Genetically encoded synthesis provides exquisite control over the design and tunability of ELP nanoparticles for drug delivery, as it enables the size and shape of the nanoparticle to be controlled,^{19,24} as well as the site and stoichiometry of small molecule drug conjugation,^{14,25} and allows introduction of targeting protein or peptide domains.²⁶ However, because of the limited chemical diversity available with the naturally occurring amino acids, we cannot simultaneously control all of these parameters in the same nanoparticle. Chemically reactive lysine and cysteine residues are typically used for site-specific attachment of small molecule drugs and imaging agents;^{27,28} this approach only works well with polypeptide nanoparticles or carrier proteins that do not include these residues in their native sequence. Unfortunately, the inclusion of most targeting proteins exposes the limitations of this approach because cysteine and lysine residues are often integral to the bioactivity of these domains and found in solvent-accessible, and hence highly reactive, locations.^{29,30}

To develop a universal approach for the site-specific attachment of extrinsic moieties to ELP nanoparticle-based drug delivery systems without cross-reactivity with a protein targeting domain, we chose to investigate the co-translational incorporation of an unnatural amino acid (UAA) into ELPs that provides a unique, bio-orthogonal reactive moiety in its side-chain for site specific attachment of small molecule drugs or imaging agents. The novel technology we describe herein represents, to the best of our knowledge, the first actively targeted, polypeptide-based nanoparticle with site-specific drug conjugation against a complex background of reactive amino acids that is made possible only through the introduction of bioorthogonal attachment chemistry.

We chose the approach of genetic code expansion pioneered by Schultz and co-workers to incorporate a bio-orthogonal residue, *p*-acetylphenylalanine (*p*AcF), as the site of drug attachment.³¹ The incorporation of *p*AcF introduces a novel reactive ketone that can participate in bioorthogonal conjugation reactions. Our approach uses a specifically evolved *M. jannaschii* tRNA^{Tyr} that recognizes the amber stop codon in *E. coli*, and its cognate, evolved *M. jannaschii* aminoacyl tRNA synthetase (aaRS^{Tyr}), allowing site-specific incorporation of Tyr analogs at the stop codon with high yield and >95% efficiency.³² We also used a recoded strain of *E. coli* that has recently been developed for UAA incorporation (C321.ΔA) as the expression host.^{33,34} This strain has all 321 amber stop codons in its genome recoded to the ochre stop codon and the corresponding release factor 1 deleted, which greatly improves the yield of UAA incorporation into proteins.³⁵

We chose the EgA1 nanobody, a small antibody fragment derived from camelid single-chain antibodies, as the targeting domain for our system.³⁶ Nanobodies are compact and are therefore unlikely to perturb self-assembly of the ELP into nanoparticles when appended on the corona, and unlike full-length antibodies, they can be expressed recombinantly in *E. coli* alone or as fusions.³⁷ Importantly, the EgA1 nanobody contains four lysine residues and a pair of cysteine residues, thereby representing a good candidate to validate the generality of our approach. The EgA1 nanobody recognizes and binds to human epidermal growth factor receptor (EGFR) with an affinity of 276 nM.³⁸ We chose EGFR as the target, as it is highly upregulated or aberrantly expressed in multiple cancer types including breast, ovarian, brain, lung, and as many as 30% of all carcinomas.^{39–41}

As the cytotoxic payload for our system, we chose a small molecule chemotherapeutic, Doxorubicin (Dox). Dox stabilizes an intermediate covalent complex between topoisomerase II and genomic DNA, causing damaging double-stranded breaks and exit from the cell cycle,⁴² and is widely used for the treatment of hematopoietic malignancies, breast, lung, ovary, stomach, and thyroid carcinomas, and bone and soft tissue sarcomas.^{16,25,43,44} However, Dox exhibits dose-limiting myelosuppression, mucositis, and cardiotoxicity, and a targeted nanoparticle formulation of this drug greatly improves its *in vivo* performance and reduces off-target toxicity.^{45,46}

The design of our Dox-loaded nanoparticles is illustrated in Figure 1A. We designed and synthesized a gene that encodes a




Figure 1. Design and expression of pAcF-ELP_{BC}-EgA1. (A) Schematic showing design and assembly of Dox-pAcF-ELP_{BC}-EgA1 nanoparticles. Dox (red) is conjugated to the pAcF residue (dark gray) at the N-terminus of the amphiphilic ELP_{BC} chain (blue) by a telechelic hydroxylamine linker (yellow). The hydrophilic ELP block is fused to the EgA1 nanobody (green) by a flexible hinge (black). (B) SDS-PAGE of pAcF-ELP_{BC}-EgA1 in C321.ΔA (lane 2) and SHuffle *E. coli* (lane 3). (C) Fluorescence imaging of SDS-PAGE qualitatively confirms reactivity of the ketone group on the pAcF residue in pAcF-ELP_{BC} (lane 2) and pAcF-ELP_{BC}-EgA1 (lane 3) with a hydroxylamine dye. ELP_{BC} without pAcF incorporated is not labeled (lane 4). (D) Tryptic digest of these constructs followed by MALDI-TOF-MS shows a single peak that is consistent with the incorporation of a pAcF residue in pAcF-ELP_{BC}-EgA1 of protein expressed in (D) C321.ΔA (1296.66 *m/z*) and (E) SHuffle *E. coli* (1296.81 *m/z*).

self-assembling diblock ELP fused to a peptide leader at the N-terminus of the hydrophobic block that incorporates the site of Dox attachment, pAcF, and the EgA1 nanobody at the C-terminus of the hydrophilic block (pAcF-ELP_{BC}-EgA1, Table S1). We designed the diblock ELP in this construct so that it has a critical micellization temperature (CMT) that lies between room temperature and body temperature. Upon heating to a temperature above the CMT, the N-terminal hydrophobic ELP block desolvates, while the C-terminal hydrophilic ELP block remains solvated, creating an

amphiphile that self-assembles into nanoscale micelles that are stable at physiological temperatures. The EgA1 nanobody is displayed on the corona of the micelle, while Dox is sequestered in the core of and is covalently attached to the ketone group of *pAcF* via a linker that creates a pH-sensitive oxime bond between the drug and the ELP,^{47,48} allowing for release of Dox in the acidic lysosomal compartments of cells after uptake by receptor-mediated endocytosis.

We expressed a library of constructs in *E. coli* from a plasmid-borne gene for these studies (Tables S1 and S2). In addition to our primary construct of interest, *pAcF*-ELP_{BC}-EgA1, our library includes the base diblock ELP (ELP_{BC}), a *pAcF*-containing ELP_{BC} without the EgA1 nanobody that serves as a negative control for targeting (*pAcF*-ELP_{BC}), and a targeted ELP_{BC} without a *pAcF* residue that serves as negative control for site-specific Dox conjugation (ELP_{BC}-EgA1). We expressed these proteins in one of three *E. coli* expression hosts; the base diblock ELP_{BC} was solubly expressed in high yield (160 mg L⁻¹) in the standard protein expression cell line, BL21(DE3). The introduction of the *pAcF* residue and EgA1 nanobody directed us to investigate the use of two different *E. coli* lines previously reported for expression of constructs containing these elements.^{35,49} The constructs containing *pAcF*, *pAcF*-ELP_{BC} and *pAcF*-ELP_{BC}-EgA1, were expressed in the genomically recoded C321.ΔA cell line with yields of 30 mg L⁻¹ and 15 mg L⁻¹, respectively. For constructs including the EgA1 nanobody, ELP_{BC}-EgA1 and *pAcF*-ELP_{BC}-EgA1, which introduces a disulfide bond into the protein, we used the SHuffle T7 Express *E. coli*, as this line is optimized to enhance disulfide bond formation and protein solubility. We were able to express these two constructs as soluble proteins in high yield (50 mg L⁻¹ and 12 mg L⁻¹, respectively). We explored expression of our final product, *pAcF*-ELP_{BC}-EgA1, in both SHuffle and C321.ΔA *E. coli* as each provides a unique advantage for expression. The engineered SHuffle strain expresses heterologous chaperones to enhance the production of functional, soluble disulfide-bonded protein under the control of a T7 promoter. Conversely, the recoded C321.ΔA strain is ideally suited for unnatural amino acid incorporation with an unassigned stop codon that can be reassigned exclusively for an unnatural residue of interest as well as the corresponding release factor deleted to eliminate any competition with a termination signal.

We purified all constructs by inverse transition cycling (ITC), a nonchromatographic method for the purification of ELPs and their fusions that exploits the LCST phase behavior of ELPs.^{50,51} SDS-PAGE of ITC-purified *pAcF*-ELP_{BC}-EgA1 from C321.ΔA and SHuffle T7 Express *E. coli* showed that four cycles of ITC provided protein with >95% purity (Figure 1B). The SDS-PAGE of all other constructs is shown in Figure S1.

We investigated the incorporation of *pAcF* with a labeling experiment wherein *pAcF*-ELP_{BC} and *pAcF*-ELP_{BC}-EgA1 were reacted with ketone-reactive Alexa697-hydroxylamine dye (Figure 1C). Fluorescence imaging of SDS-PAGE of the reaction product qualitatively confirms reactivity of the *pAcF*-ELP_{BC} (lane 2) and *pAcF*-ELP_{BC}-EgA1 (lane 3) with the ketone-reactive dye and hence indicated the successful incorporation of *pAcF* in these constructs.

We next confirmed the incorporation of *pAcF* in *pAcF*-ELP_{BC}-EgA1 expressed in the SHuffle and C321.ΔA cell lines by mass spectrometry. The leader peptide containing the *pAcF* residue was cleaved by trypsin and analyzed by matrix assisted laser desorption ionization time-of-flight mass spectrometry

(MALDI-TOF-MS). The observed mass of the N-terminal peptide generated by trypsin cleavage of *pAcF*-ELP_{BC}-EgA1 is 1296.66 Da for protein expressed in C321.ΔA and 1296.81 Da expressed in SHuffle, both of which are in excellent agreement with the theoretical mass of 1296.73 Da, confirming the successful incorporation of *pAcF* (Figure 1D). While we determined that either *E. coli* line would be a suitable expression host for simultaneously encoding *pAcF* and the structured EgA1 nanobody, we selected C321.ΔA for *pAcF*-ELP_{BC}-EgA1 expression for all subsequent experiments as this line provided a modestly greater yield compared to the SHuffle strain.

We further quantified the incorporation efficiency of *pAcF* with ESI-LC-MS and found >98% incorporation efficiency of *pAcF* in both *pAcF*-ELP_{BC} and *pAcF*-ELP_{BC}-EgA1 (Figure S2, Table S3). While the C321.ΔA and tRNA/synthetase pair we employed for protein expression have been optimized for greatest incorporation fidelity of *pAcF*, there is a minor population, < 2%, of natural amino acids misincorporated at the *pAcF* site. The misincorporated residues we detected include the aromatic Tyr, Trp, and Phe, consistent with literature reports for this cell line.^{34,52–54}

We next validated the bioactivity of the EgA1 nanobody by flow cytometry. We examined the binding of ELP_{BC}-EgA1 for EGFR and cellular uptake in a panel of eight cell lines with a range of EGFR expression levels to identify candidate cell lines for *in vitro* testing of our conjugates (Figure 2, Figures S3 and S4). To perform flow cytometry analysis, we fluorescently labeled the N-termini of both ELP_{BC}-EgA1 and ELP_{BC} with AlexaFluor488-NHS ester, incubated the labeled proteins with the different cell lines, and analyzed the cells by flow cytometry. In a mouse NIH3T3 fibroblast line transfected with human EGFR (NIH3T3 EGFR+) that has a high level of EGFR expression (1.5 × 10⁶ receptors per cell),⁵⁵ ELP_{BC}-EgA1 exhibited 18-fold higher uptake as compared to the nontargeted ELP_{BC} (Figure 2A,D). Two cell lines with a range of reported sensitivity to Dox^{56,57} also exhibited significantly higher uptake as compared to ELP_{BC}. These are the squamous carcinoma line A431, that showed a 13-fold higher uptake as compared to the nontargeted ELP_{BC} (Figure 2B,D), and the ovarian adenocarcinoma line SKOV-3 that exhibited a five-fold higher uptake of ELP_{BC}-EgA1 than ELP_{BC} (Figure 2C,D). Flow cytometry experiments with a negative control, the untransfected fibroblast cell line (NIH3T3 EGFR-) showed no significant difference between uptake of the targeted and nontargeted constructs, confirming the specificity of the EgA1 nanobody for EGFR (Figure S3E,F).

We next visualized the intracellular uptake of fluorescently labeled ELP_{BC}-EgA1 in the EGFR-transfected fibroblast line by fluorescence microscopy (Figure 2E). After 24 h of incubation of NIH3T3 EGFR+ cells with Alexa488-ELP_{BC}-EgA1, high levels of intracellular accumulation of the labeled protein were observed. We confirmed specificity of the EgA1 nanobody by coinubating Alexa488-ELP_{BC}-EgA1 with a 10-fold molar excess of unlabeled ELP_{BC}-EgA1 to compete with the Alexa488-ELP_{BC}-EgA1 for binding to EGFR; these cells show little intracellular fluorescence, as do cells incubated with the negative control, Alexa488-ELP_{BC}. We further confirmed the specificity of EgA1 for EGFR by preincubating cells with excess, fluorescently labeled EGF followed by Alexa647-ELP_{BC}-EgA1. We observed simultaneously high levels of intracellular EGF and little Alexa647-ELP_{BC}-EgA1, whereas uptake of Alexa647-ELP_{BC}-EgA1 was significant in a control




Figure 2. Flow cytometry confirms specificity of the EgA1 nanobody for human epidermal growth factor receptor (EGFR). Fluorescently labeled ELP_{BC}-EgA1 or ELP_{BC} were incubated with various cell lines and analyzed by flow cytometry. (A) NIH3T3 murine fibroblasts transfected with human EGFR (NIH3T3 EGFR+); (B) A431 squamous carcinoma cells; and (C) SKOV-3 ovarian adenocarcinoma cells all indicate enhanced uptake of the ELP_{BC}-EgA1 as compared to ELP_{BC}. (D) Geometric mean fluorescent intensities (gMFI) of the cell populations were used to quantify the fold uptake of ELP_{BC}-EgA1 over ELP_{BC} and shows the range of nanobody-mediated targeting of EGFR across the cell lines. (E) Fluorescence microscopy images of NIH3T3 EGFR+ cells incubated with AlexaFluor488-ELP_{BC}-EgA1, AlexaFluor488-ELP_{BC}-EgA1 with 10-fold excess unlabeled ELP_{BC}-EgA1, and AlexaFluor488-ELP_{BC} shows increased uptake of the AlexaFluor488-ELP_{BC}-EgA1 construct, while the cells incubated with 10-fold excess unlabeled ELP_{BC}-EgA1 demonstrate the specificity of the EgA1 nanobody. The samples incubated with AlexaFluor488-ELP_{BC} show the basal level of nanoparticle uptake. Nuclei stained with Hoechst (blue), cell membranes stained with AlexaFluor594-wheat germ agglutinin (red), and all ELP constructs with AlexaFluor488 (green). Scale bars 25 μm.

experiment in which cells were not preincubated with EGF (Figure S5). Together, the flow cytometry and fluorescence microscopy results demonstrate that the EgA1 nanobody: (1) maintains specificity for EGFR when fused to ELP_{BC}, (2) enhances intracellular uptake of an ELP_{BC} fusion by cells that overexpress EGFR, and (3) can be used for targeting the ELP_{BC} to a panel of human cancer cell lines that overexpress EGFR.

We next used the bioorthogonal ketone group on the pAcF residue as the site of conjugation for our drug payload, Dox. To conjugate Dox to pAcF, we employed a two-step reaction scheme (Figure 3A, Table S4). First, we activated pAcF in **1** with an excess of the telechelic linker **2**. While the reaction with pAcF-ELP_{BC} proceeds at pH 4.0 with high efficiency (74.5%), we found the presence of aniline catalyst⁵⁸ allowed the reaction to proceed nearly to completion (90.9%) at pH 6.2, a pH that is more optimal for the stability of pAcF-ELP_{BC}-EgA1 (see eq S1 for calculation of Dox labeling efficiency). We removed unreacted linker by centrifugal ultrafiltration and then reacted the intermediate construct **3** with an excess of Dox **4** in the presence of aniline and removed unreacted Dox using ultrafiltration from the final product **5**. We confirmed each individual reaction step by digesting the products **1**, **3**, and **5** with trypsin and analyzing the digested peptide fragments by MALDI-TOF-MS. The spectra of the liberated peptides showed one major peak for each product, which increased in




Figure 3. Confirming Dox attachment and acid-catalyzed release from pAcF-ELP_{BC} and pAcF-ELP_{BC}-EgA1. (A) Schematic of the two-step Dox conjugation to pAcF. First, pAcF-ELP_{BC} **1** is reacted with the hydroxylamine linker **2** in the presence of 10 mM aniline catalyst to form the intermediate **3**. This product is purified and reacted excess doxorubicin **4** under the same conditions to form the final conjugate **5**. (B) The leader peptide containing pAcF can be liberated by tryptic digest from pAcF-ELP_{BC} to confirm successful reaction steps via matrix assisted laser desorption/ionization mass spectrometry (MALDI-TOF): first, incorporation of pAcF in **1** (expected MW 1296.73 Da, observed 1296.65 Da), then modification with linker in **3** (expected MW 1384.84 Da, observed 1384.78 Da), and finally conjugation of Dox onto **5** (expected MW 1911.41 Da, observed 1910.15 Da). (C) Attachment of Dox to pAcF-ELP_{BC}-EgA1 and purity of the final conjugate is confirmed using size exclusion chromatography (SEC), analyzing the spectrum at both A220 nm, to monitor the elution time of the conjugate, and A488 nm, the characteristic absorbance of Dox, to confirm attachment and purity. (D) pH-dependent release of Dox from Dox-pAcF-ELP_{BC}-EgA1 is assessed by SEC at pH 4.0 (green) and pH 7.4 (grey).

molecular weight by the expected amount after each reaction step (Figure 3B, full spectra Figure S6). We further validated linker and Dox attachment after each reaction step with ESI-LC/MS and analyzed the composition of the reaction products (Figure S7, Table S3). We found each reaction step had >85% of the desired product and minor populations of starting material and dimer reaction products. We confirmed purity of our final reaction product using size exclusion chromatography (SEC) and the characteristic absorbance of Dox at 488 nm (Figure 3C, Figure S8). We validated the mechanism of Dox release, acid-catalyzed oxime hydrolysis, by incubating solutions of Dox-pAcF-ELP_{BC}-EgA1 conjugates in either pH 4.0 or pH 7.4 buffer and quantifying the amount of Dox released at various time points with SEC (Figure 3D). We observed steady-state release of $58.2 \pm 1.4\%$ after incubation for 48 h in pH 4.0 buffer and negligible release at pH 7.4,

indicating these micelles will release drug only after receptor-mediated endocytosis into acidic lysosomal compartments.

We characterized the size and shape of both the Dox-*pAcF-ELP_{BC}-EgA1* and nontargeted control Dox-*pAcF-ELP_{BC}* nanoparticles by light scattering and cryogenic transmission electron microscopy (cryo-TEM). Dynamic light scattering (DLS), performed in dilute solution as a function of temperature, showed the critical micellization temperature (CMT) of both *pAcF-ELP_{BC}-EgA1* and *pAcF-ELP_{BC}* to be $\sim 32^\circ\text{C}$ and unchanged upon conjugation of Dox (Figure 4A). The Dox-




Figure 4. Dox conjugates form uniform nanoparticles at physiologic temperatures. (A) Characterization of the particle self-assembly by dynamic light scattering (DLS) shows hydrodynamic radius (R_h) as a function of temperature for *pAcF-ELP_{BC}-EgA1* (green) and *pAcF-ELP_{BC}* (gray) before and after Dox conjugation. (B) Polydispersity of the samples by % mass at temperatures below (25°C , unimers) and above (35°C , micelles) the critical micellization temperature (CMT). Visualization of the micelles by cryogenic transmission electron microscopy (cryo-TEM) illustrates the monodispersity of the nanoscale assemblies of (C) Dox-*pAcF-ELP_{BC}-EgA1* and (D) Dox-*pAcF-ELP_{BC}*. Scale bars 200 nm.

pAcF-ELP_{BC}-EgA1 construct assembles into monodisperse nanoparticles with a hydrodynamic radius (R_h) of 44.7 ± 4.4 nm, while the Dox-*pAcF-ELP_{BC}* construct forms smaller particles with a R_h of 23.7 ± 0.9 nm (Figure 4B). A dilution series of Dox-*pAcF-ELP_{BC}-EgA1* analyzed by DLS revealed the critical micellization concentration (CMC) to be between 1 and $5\ \mu\text{M}$, consistent with findings for other *ELP_{BC}* nanoparticles (Figure S9).²⁶ Static light scattering (SLS) revealed the Dox-*pAcF-ELP_{BC}-EgA1* particles to contain approximately 22 chains per particle, while the Dox-*pAcF-ELP_{BC}* particles contain approximately 28 chains per particle (Table 1, Figure S10). The positively charged EgA1 nanobody

Table 1. Static Light Scattering of Dox-*pAcF-ELP_{BC}* and Dox-*pAcF-ELP_{BC}-EgA1* Performed at 35°C , above the CMT

	R_g^a (nm)	R_h^b (nm)	ρ^c	MW_{micelle} (g mol ⁻¹)	N_{agg}^d
Dox- <i>pAcF-ELP_{BC}</i>	20.3	18.4	1.1	1.85×10^6	27.8
Dox- <i>pAcF-ELP_{BC}-EgA1</i>	37.2	41.8	0.9	1.63×10^6	21.8

^a R_g , radius of gyration. ^b R_h , hydrodynamic radius. ^c ρ , form factor. ^d N_{agg} , number of chains per micelle.

(pI 9.08) likely increases Dox-*pAcF-ELP_{BC}-EgA1* particle size while reducing the N_{agg} by charge repulsion as compared to Dox-*pAcF-ELP_{BC}*. Together with the Dox conjugation efficiency, this indicates each EgA1-targeted nanoparticle is loaded with 17–18 Dox molecules.

We visualized both particles with cryo-TEM to further confirm their spherical shape and size (Figure 4C, 4D, Figure S11). Core sizing analysis of these particles indicated roughly equivalent core diameters of 24.7 ± 4.4 nm for the Dox-*pAcF-ELP_{BC}* particles and 29.4 ± 6.2 nm for the Dox-*pAcF-ELP_{BC}-EgA1* nanoparticles. This further indicates the increased size of the Dox-*pAcF-ELP_{BC}-EgA1* particles is due to size differences in the corona, where the EgA1 nanobody is presented. These studies confirm that the Dox-loaded particles are spherical, stable above their CMT at physiological temperature (37°C), and in the ideal sub-100 nm size range for tumor penetration,⁵⁹ making them suitable for the delivery of drugs to solid tumors.

We next evaluated the cytotoxicity of the Dox-*pAcF-ELP_{BC}-EgA1* and Dox-*pAcF-ELP_{BC}* particles in two EGFR positive cell lines: A431 and SKOV-3.^{60,61} We chose these two tumor lines, as they express different level of the EGFR, with A431 expressing higher levels of EGFR than SKOV-3. Examining the response of tumor cells that have different levels of receptor expression is critical to demonstrate the clinical utility of our platform, as EGFR expression level varies widely between cancer types,⁶² within individual tumors,⁶³ and at different time points of treatment.⁶⁴ These two cell lines also differ in their relative sensitivity to Dox, with the A431 line being more sensitive than SKOV-3. After treatment with increasing concentrations of free drug and assessing cell viability, we determined the IC_{50} of Dox in A431 cells is $1.38\ \mu\text{M}$, while that of SKOV-3 cells is $31.8\ \mu\text{M}$ (Figure 5A, 5B). While A431 represents the ideal tumor for targeted drug treatment as it is a highly receptor-positive, drug-sensitive line, SKOV-3 represents a more clinically relevant subset of tumor cells, those with intermediate receptor expression and a lower sensitivity to Dox.⁵⁷

We treated the two cell lines with increasing concentrations of the targeted and nontargeted Dox conjugates and measured cell viability after treatment. In both cell lines, the Dox-*pAcF-ELP_{BC}-EgA1* particles have significantly lower IC_{50} values than the nontargeted control Dox-*pAcF-ELP_{BC}* particles, confirming the therapeutic utility of the targeting domain in an *in vitro* setting (Figure 5C). We further analyzed the data by normalizing the IC_{50} values of the targeted Dox-*pAcF-ELP_{BC}-EgA1* to that of free Dox, as it illustrates the effect of targeting on treatment efficacy (Figure 5D). Importantly, in the SKOV-3 line with lower Dox sensitivity, the presence of the targeting domain drives the IC_{50} to be lower than that of free drug (normalized value 0.84), strongly highlighting the ability of this targeting domain to enhance the cytotoxicity of Dox. Because the A431 line is already highly sensitive to free drug, it is therefore difficult to affect the cytotoxic threshold, and we observe a modest increase in IC_{50} of the targeted therapy as compared to free Dox. Nevertheless, in both cell lines, the decrease in IC_{50} over an order of magnitude with the targeted as compared to nontargeted control indicates a significant widening of the therapeutic window. This attribute of the targeted construct, along with the potential benefits for improved pharmacokinetics and tumor accumulation³ by delivering a drug in a nanoparticle formulation *in vivo* is likely to far outweigh the observed higher *in vitro* cytotoxicity of free drug. The fusions without attached Dox exhibited no




Figure 5. EgA1-targeted Dox-pAcF-ELP_{BC}-EgA1 is significantly more potent in cancer cells via lysosomal-mediated release. Cytotoxicity of Dox-pAcF-ELP_{BC}-EgA1 (green), Dox-pAcF-ELP_{BC} (blue), and free Dox (gray) in (A) A431 and (B) SKOV-3 cells. (C) IC₅₀ values of these cell viability assays confirms the targeted Dox-pAcF-ELP_{BC}-EgA1 is more cytotoxic than the nontargeted control, Dox-pAcF-ELP_{BC}. $p < 0.001$. (D) Normalized IC₅₀ of Dox-pAcF-ELP_{BC}-EgA1 to IC₅₀ of free Dox indicates the effect of active targeting on the cytotoxicity of Dox. Spinning disk confocal imaging of A431 cells incubated with Dox-pAcF-ELP_{BC}-EgA1 or Dox-pAcF-ELP_{BC} for (E) 4 h or (F) 24 h. Hoechst (blue) staining shows nuclei, CytoPainter (green) indicates low pH endolysosomal compartments, and Dox (red) shows subcellular localization of Dox conjugates. Merged images show colocalization (yellow) between lysosomes and Dox. Scale bars 20 μm.

cytotoxicity, indicating that neither EgA1 nor the ELP contributed to cytotoxicity observed for the Dox-conjugated constructs (Figure S12).

To investigate the subcellular trafficking of these particles after uptake, we imaged the Dox-loaded particles using spinning-disk confocal microscopy in the A431 cell line. We incubated adherent A431 cells with Dox-pAcF-ELP_{BC}-EgA1 and Dox-pAcF-ELP_{BC} for 4 h (Figure 5E, Figure S13A,B) and 24 h (Figure 5F, Figure S13C,D). We then imaged colocalization of Dox with endolysosomes by staining cells with a lysosomal tracking dye, CytoPainter LysoDeep Red, that selectively accumulates and fluoresces in the acidic late endosomal and lysosomal compartments (pH 4.5–4.8). In cells stained with CytoPainter, we found significantly greater

intracellular accumulation of Dox delivered by Dox-pAcF-ELP_{BC}-EgA1 compared to Dox-pAcF-ELP_{BC}. We also found colocalization of Dox and CytoPainter at both 4 and 24 h of incubation, with the effect being more pronounced at 24 h. We evaluated the degree of colocalization with Pearson's R coefficient. This metric is a measure of the linear correlation between two variables, herein the fluorescence intensities for Dox and CytoPainter at each pixel location in the confocal images. $R = 1.0$ indicates a perfect linear relationship and hence exact colocalization of the drug with endolysosomes, and $R = -1.0$ indicates a negative linear correlation between the two variables, and in this context indicates a complete lack of colocalization of Dox with endolysosomes (Figure S13E).^{65,66} The Dox-pAcF-ELP_{BC}-EgA1 samples increased in endolysosomal colocalization from $R = 0.66$ to $R = 0.76$ from 4 to 24 h incubation. Conversely, the nontargeted control Dox-pAcF-ELP_{BC} had $R < 0.5$ at both time points, indicating little colocalization and suggesting a longer time required for uptake of these particles, which results in the lower efficacy observed in the *in vitro* cytotoxicity studies.

We also confirmed the intensity of lysosomal dye was similar between all four regions of interest analyzed to ensure that the observed differences in colocalization were not due to a different number of, or intensity of, lysosomes analyzed in the different images (Figure S13F). These colocalization analyses revealed both (1) greater levels of and (2) a time-dependent increase in endolysosomal colocalization with Dox-pAcF-ELP_{BC}-EgA1 as compared to the nontargeted Dox-pAcF-ELP_{BC}. This demonstrates that the receptor-mediated endocytosis of the EgA1-containing construct concurrently promotes both more rapid entry into the cell and pH-mediated drug release. Taken together, these *in vitro* experiments validate that the active targeting of Dox-pAcF-ELP_{BC}-EgA1 directly translates into the exceptional tumor cytotoxicity of this construct.

The platform we have developed combines a bioorthogonal reactive group with high-affinity targeting in a single protein-based particle and has three distinct advantages over existing approaches: (1) our biopolymer vehicle ensures monodisperse, nontoxic nanoparticles with starting materials that are easily produced recombinantly by overexpression in *E. coli* and purified at high yield via its LCST phase behavior; (2) the location of drug-loading is precisely specified, and the orthogonal UAA-mediated drug conjugation chemistry permits the inclusion of the cysteine-containing targeting domain into the construct; (3) the EgA1 nanobody delivers the targeted drug-loaded nanoparticles to EGFR-positive cancer cells via receptor-mediated endocytosis.^{67,68} While previous approaches to cancer nanotherapeutics have directed targeting of nanoparticles with scaffold proteins,^{69,70} utilized UAAs for biorthogonal drug attachment,^{71–73} and formulated biopolymer nanoparticles as small molecule drug carriers,^{74,75} our platform is the first to combine these three elements into one powerful therapeutic agent.

In conclusion, the platform described herein reveals a promising strategy for simultaneously genetically encoding both a drug conjugation site and structured bioactive domain into a biopolymer-based nanoparticle, an approach previously inaccessible with existing techniques. The use of an unnatural amino acid as the site of drug attachment allows for the incorporation of a nanobody as the targeting element, which requires a disulfide bond for its stability. Our platform maintains site-specificity of drug attachment against the

complex chemical background of proteins that have a distribution of reactive amino acids. This study is the first example of using molecular engineering to decouple the drug reactivity from any polypeptide or protein of interest; our highly tunable system can be modified and expanded upon to incorporate a variety of cytotoxic drugs or active targeting domains. We anticipate future work will validate the efficacy of these carriers in a range of tumor types *in vivo* to elucidate the full therapeutic potential of our multifunctional targeted, drug-loaded biopolymer nanoparticles.

■ ASSOCIATED CONTENT

Supporting Information

The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acs.nanolett.8b03837.

Amino acid sequences of proteins used in this study, protein expression and Dox reaction conditions, size exclusion chromatography traces, dynamic and static light scattering, flow cytometry, control cell viability assays, cryoTEM and confocal imaging, mass spectrometry data (PDF)

■ AUTHOR INFORMATION

Corresponding Author

*E-mail: chilkoti@duke.edu.

ORCID

Michael J. Dzuricky: 0000-0002-1775-2132

Ashutosh Chilkoti: 0000-0002-1569-2228

Present Address

[†]Department of Chemistry, Syracuse University, Syracuse, New York 13244, United States.

Author Contributions

S.A.C. conceptualized, designed, and performed experiments, analyzed data, and wrote the manuscript. D.M. assisted with data analysis and experimental design. M.J.D. performed SLS and cryoTEM experiments and analyzed these data. F.J.I. provided materials and support. E.M.B. and A.C. conceptualized the project, assisted with data analysis, and edited the manuscript. All authors have given approval to the final version of the manuscript.

Funding

This work was supported by NIH R01 EB00188 to A.C.

Notes

The authors declare no competing financial interest.

■ ABBREVIATIONS

ELP, elastin-like polypeptide; ELP_{BC}, ELP diblock copolymer; UAA, unnatural amino acid; pAcF, p-acetylphenylalanine; EGFR, epidermal growth factor receptor; Dox, Doxorubicin; CMT, critical micellization temperature; CMC, critical micellization concentration; MALDI-TOF-MS, matrix assisted laser desorption ionization-time-of-flight mass spectroscopy; DLS, dynamic light scattering; SLS, static light scattering; SEC, size exclusion chromatography; cryoTEM, cryogenic transmission electron microscopy.

■ REFERENCES

- (1) Cho, K.; Wang, X.; Nie, S.; Chen, Z. G.; Shin, D. M. *Clin. Cancer Res.* **2008**, *14* (5), 1310–6.
- (2) Yoo, J.-W.; Chambers, E.; Mitragotri, S. *Curr. Pharm. Des.* **2010**, *16* (21), 2298–2307.
- (3) Blanco, E.; Shen, H.; Ferrari, M. *Nat. Biotechnol.* **2015**, *33* (9), 941–51.
- (4) Bazak, R.; Hourri, M.; El Achy, S.; Kamel, S.; Refaat, T. J. *Cancer Res. Clin. Oncol.* **2015**, *141* (5), 769–84.
- (5) Bertrand, N.; Wu, J.; Xu, X.; Kamaly, N.; Farokhzad, O. C. *Adv. Drug Delivery Rev.* **2014**, *66*, 2–25.
- (6) Hao, Y.; Zheng, C.; Wang, L.; Hu, Y.; Guo, H.; Song, Q.; Zhang, H.; Zhang, Z.; Zhang, Y. J. *Mater. Chem. B* **2017**, *5* (11), 2133–2144.
- (7) Werengowska-Ciećwierz, K.; Wiśniewski, M.; Terzyk, A. P.; Furmaniak, S. *Adv. Condens. Matter Phys.* **2015**, *2015*, 1–27.
- (8) Matsumura, Y.; Maeda, H. *Cancer Res.* **1986**, *46* (12), 6387–6392.
- (9) Dreher, M. R.; Simnick, A. J.; Fischer, K.; Smith, R. J.; Patel, A.; Schmidt, M.; Chilkoti, A. J. *Am. Chem. Soc.* **2008**, *130* (2), 687–694.
- (10) Torchilin, V. P.; Lukyanov, A. N. *Drug Discovery Today* **2003**, *8* (6), 259–266.
- (11) Meyer, D. E.; Chilkoti, A. *Biomacromolecules* **2002**, *3* (2), 357–367.
- (12) Navon, Y.; Bitton, R. *Isr. J. Chem.* **2016**, *56* (8), 581–589.
- (13) Nettles, D. L.; Chilkoti, A.; Setton, L. A. *Adv. Drug Delivery Rev.* **2010**, *62* (15), 1479–85.
- (14) Bhattacharyya, J.; Bellucci, J. J.; Weitzhandler, I.; McDaniel, J. R.; Spasojevic, I.; Li, X.; Lin, C. C.; Chi, J. T.; Chilkoti, A. *Nat. Commun.* **2015**, *6*, 7939.
- (15) Liu, W.; Dreher, M. R.; Furgeson, D. Y.; Peixoto, K. V.; Yuan, H.; Zalutsky, M. R.; Chilkoti, A. J. *Controlled Release* **2006**, *116* (2), 170–8.
- (16) Mastris, E. M.; Chen, M.; McDaniel, J. R.; Li, X.; Hyun, J.; Dewhirst, M. W.; Chilkoti, A. J. *Controlled Release* **2015**, *208*, 52–8.
- (17) Urry, D. W.; Hugel, T.; Seitz, M.; Gaub, H. E.; Sheiba, L.; Dea, J.; Xu, J.; Parker, T. *Philos. Trans. R. Soc., B* **2002**, *357* (1418), 169–84.
- (18) Chilkoti, A.; Christensen, T.; MacKay, J. A. *Curr. Opin. Chem. Biol.* **2006**, *10* (6), 652–7.
- (19) MacEwan, S. R.; Weitzhandler, I.; Hoffmann, I.; Genzer, J.; Gradzielski, M.; Chilkoti, A. *Biomacromolecules* **2017**, *18* (2), 599–609.
- (20) Trabbic-Carlson, K.; Meyer, D. E.; Liu, L.; Piervincenzi, R.; Nath, N.; LaBean, T.; Chilkoti, A. *Protein Eng., Des. Sel.* **2004**, *17* (1), 57–66.
- (21) Callahan, D. J.; Liu, W.; Li, X.; Dreher, M. R.; Hassounah, W.; Kim, M.; Marszalek, P.; Chilkoti, A. *Nano Lett.* **2012**, *12* (4), 2165–70.
- (22) MacKay, J. A.; Chen, M.; McDaniel, J. R.; Liu, W.; Simnick, A. J.; Chilkoti, A. *Nat. Mater.* **2009**, *8* (12), 993–9.
- (23) McDaniel, J. R.; MacEwan, S. R.; Li, X.; Radford, D. C.; Landon, C. D.; Dewhirst, M.; Chilkoti, A. *Nano Lett.* **2014**, *14* (5), 2890–2895.
- (24) Weitzhandler, I.; Dzuricky, M.; Hoffmann, I.; Garcia Quiroz, F.; Gradzielski, M.; Chilkoti, A. *Biomacromolecules* **2017**, *18* (8), 2419–2426.
- (25) McDaniel, J. R.; MacEwan, S. R.; Dewhirst, M.; Chilkoti, A. J. *Controlled Release* **2012**, *159* (3), 362–7.
- (26) Wang, J.; Dzuricky, M.; Chilkoti, A. *Nano Lett.* **2017**, *17* (10), 5995–6005.
- (27) Raphael, J.; Parisi-Amon, A.; Heilshorn, S. J. *Mater. Chem.* **2012**, *22* (37), 19429–19437.
- (28) Lim, D. W.; Nettles, D. L.; Setton, L. A.; Chilkoti, A. *Biomacromolecules* **2007**, *8* (5), 1463–70.
- (29) Boohaker, R. J.; Lee, M. W.; Vishnubhotla, P.; Perez, J. M.; Khaled, A. R. *Curr. Med. Chem.* **2012**, *19* (22), 3794–3804.
- (30) Shehu, A.; Kavraki, L. E.; Clementi, C. *Protein Sci.* **2008**, *17* (3), 482–93.
- (31) Wang, L.; Zhang, Z.; Brock, A.; Schultz, P. G. *Proc. Natl. Acad. Sci. U. S. A.* **2003**, *100* (1), 56–61.
- (32) Liu, C. C.; Schultz, P. G. *Annu. Rev. Biochem.* **2010**, *79*, 413–44.

- (33) Isaacs, F. J.; Carr, P. A.; Wang, H. H.; Lajoie, M. J.; Sterling, B.; Kraal, L.; Tolonen, A. C.; Gianoulis, T. A.; Goodman, D. B.; Reppas, N. B.; Emig, C. J.; Bang, D.; Hwang, S. J.; Jewett, M. C.; Jacobson, J. M.; Church, G. M. *Science* **2011**, 333 (6040), 348–53.
- (34) Lajoie, M. J.; Rovner, A. J.; Goodman, D. B.; Aerni, H. R.; Haimovich, A. D.; Kuznetsov, G.; Mercer, J. A.; Wang, H. H.; Carr, P. A.; Mosberg, J. A.; Rohland, N.; Schultz, P. G.; Jacobson, J. M.; Rinehart, J.; Church, G. M.; Isaacs, F. J. *Science* **2013**, 342 (6156), 357–60.
- (35) Amiram, M.; Haimovich, A. D.; Fan, C.; Wang, Y.-S.; Aerni, H. R.; Ntai, I.; Moonan, D. W.; Ma, N. J.; Rovner, A. J.; Hong, S. H.; Kelleher, N. L.; Goodman, A. L.; Jewett, M. C.; Soll, D.; Rinehart, J.; Isaacs, F. J. *Nat. Biotechnol.* **2015**, 33 (12), 1272–1279.
- (36) Muyldermans, S. *Annu. Rev. Biochem.* **2013**, 82, 775–97.
- (37) Roovers, R. C.; Laeremans, T.; Huang, L.; De Taeye, S.; Verkleij, A. J.; Revets, H.; de Haard, H. J.; van Bergen en Henegouwen, P. M. P. *Cancer Immunol. Immunother.* **2007**, 56 (3), 303–317.
- (38) Hofman, E. G.; Ruonala, M. O.; Bader, A. N.; van den Heuvel, D.; Voortman, J.; Roovers, R. C.; Verkleij, A. J.; Gerritsen, H. C.; van Bergen en Henegouwen, P. M. P. *J. Cell Sci.* **2008**, 121 (15), 2519–2528.
- (39) Yewale, C.; Baradia, D.; Vhora, I.; Patil, S.; Misra, A. *Biomaterials* **2013**, 34 (34), 8690–707.
- (40) Cerami, E.; Gao, J.; Dogrusoz, U.; Gross, B. E.; Sumer, S. O.; Aksoy, B. A.; Jacobsen, A.; Byrne, C. J.; Heuer, M. L.; Larsson, E.; Antipin, Y.; Reva, B.; Goldberg, A. P.; Sander, C.; Schultz, N. *Cancer Discovery* **2012**, 2 (5), 401–4.
- (41) Gao, J.; Aksoy, B. A.; Dogrusoz, U.; Dresdner, G.; Gross, B.; Sumer, S. O.; Sun, Y.; Jacobsen, A.; Sinha, R.; Larsson, E.; Cerami, E.; Sander, C.; Schultz, N. *Sci. Signaling* **2013**, 6 (269), p11.
- (42) Rivankar, S. J. *Cancer Res. Ther.* **2014**, 10 (4), 853–8.
- (43) Dreher, M. R.; Raucher, D.; Balu, N.; Michael Colvin, O.; Ludeman, S. M.; Chilkoti, A. J. *Controlled Release* **2003**, 91 (1–2), 31–43.
- (44) Furgeson, D. Y.; Dreher, M. R.; Chilkoti, A. J. *Controlled Release* **2006**, 110 (2), 362–9.
- (45) Tacar, O.; Sriamornsak, P.; Dass, C. R. *J. Pharm. Pharmacol.* **2013**, 65 (2), 157–70.
- (46) Bi, D.; Zhao, L.; Yu, R.; Li, H.; Guo, Y.; Wang, X.; Han, M. *Drug Delivery* **2018**, 25 (1), 564–575.
- (47) Jin, Y.; Song, L.; Su, Y.; Zhu, L.; Pang, Y.; Qiu, F.; Tong, G.; Yan, D.; Zhu, B.; Zhu, X. *Biomacromolecules* **2011**, 12 (10), 3460–8.
- (48) Kalia, J.; Raines, R. T. *Angew. Chem., Int. Ed.* **2008**, 47 (39), 7523–6.
- (49) Zarschler, K.; Witcey, S.; Kapplusch, F.; Foerster, C.; Stephan, H. *Microb. Cell Fact.* **2013**, 12, 97.
- (50) Meyer, D. E.; Chilkoti, A. Protein purification by inverse transition cycling. In *Protein Interactions*; Cold Spring Harbor Laboratory Press, 2002; pp 329–343.
- (51) Meyer, D. E.; Chilkoti, A. *Nat. Biotechnol.* **1999**, 17 (11), 1112–1115.
- (52) Pirman, N. L.; Barber, K. W.; Aerni, H. R.; Ma, N. J.; Haimovich, A. D.; Rogulina, S.; Isaacs, F. J.; Rinehart, J. *Nat. Commun.* **2015**, 6, 8130.
- (53) O'Donoghue, P.; Prat, L.; Heinemann, I. U.; Ling, J.; Odoi, K.; Liu, W. R.; Soll, D. *FEBS Lett.* **2012**, 586 (21), 3931–7.
- (54) Aerni, H. R.; Shifman, M. A.; Rogulina, S.; O'Donoghue, P.; Rinehart, J. *Nucleic Acids Res.* **2015**, 43 (2), No. e8.
- (55) Pedersen, M. W.; Tkach, V.; Pedersen, N.; Berezin, V.; Poulsen, H. S. *Int. J. Cancer* **2004**, 108, 643–653.
- (56) Kibria, G.; Hatakeyama, H.; Akiyama, K.; Hida, K.; Harashima, H. *Biol. Pharm. Bull.* **2014**, 37 (12), 1926.
- (57) Yang, W.; Soares, J.; Greninger, P.; Edelman, E. J.; Lightfoot, H.; Forbes, S.; Bindal, N.; Beare, D.; Smith, J. A.; Thompson, I. R.; Ramaswamy, S.; Futreal, P. A.; Haber, D. A.; Stratton, M. R.; Benes, C.; McDermott, U.; Garnett, M. J. *Nucleic Acids Res.* **2012**, 41 (Database issue), D955–61.
- (58) Dirksen, A.; Hackeng, T. M.; Dawson, P. E. *Angew. Chem., Int. Ed.* **2006**, 45 (45), 7581–4.
- (59) Wittrup, K. D.; Thurber, G. M.; Schmidt, M. M.; Rhoden, J. J. *Methods Enzymol.* **2012**, 503, 255–68.
- (60) Wang, K.; Li, D.; Sun, L. *OncoTargets Ther.* **2016**, 9, 377–86.
- (61) Zhang, F.; Wang, S.; Yin, L.; Yang, Y.; Guan, Y.; Wang, W.; Xu, H.; Tao, N. *Anal. Chem.* **2015**, 87 (19), 9960–5.
- (62) Ponten, F.; Jirstrom, K.; Uhlen, M. *J. Pathol.* **2008**, 216 (4), 387–93.
- (63) Algars, A.; Avoranta, T.; Osterlund, P.; Lintunen, M.; Sundstrom, J.; Jokilehto, T.; Ristimaki, A.; Ristamaki, R.; Carpen, O. *PLoS One* **2014**, 9 (6), No. e99590.
- (64) Bozic, I.; Reiter, J. G.; Allen, B.; Antal, T.; Chatterjee, K.; Shah, P.; Moon, Y. S.; Yaquibie, A.; Kelly, N.; Le, D. T.; Lipson, E. J.; Chapman, P. B.; Diaz, L. A., Jr.; Vogelstein, B.; Nowak, M. A. *eLife* **2013**, 2, No. e00747.
- (65) Adler, J.; Parmryd, I. *Cytometry, Part A* **2010**, 77 (8), 733–42.
- (66) Bolte, S.; Cordelieres, F. P. J. *Microsc.* **2006**, 224 (3), 213–32.
- (67) Oliveira, S.; Schiffelers, R. M.; van der Veeken, J.; van der Meel, R.; Vongpromek, R.; van Bergen En Henegouwen, P. M.; Storm, G.; Roovers, R. C. *J. Controlled Release* **2010**, 145 (2), 165–75.
- (68) Bareford, L.; Swaan, P. *Adv. Drug Delivery Rev.* **2007**, 59 (8), 748–758.
- (69) Wang, M.; Thanou, M. *Pharmacol. Res.* **2010**, 62 (2), 90–99.
- (70) Friedman, A.; Claypool, S.; Liu, R. *Curr. Pharm. Des.* **2013**, 19 (35), 6315–6329.
- (71) Kularatne, S. A.; Deshmukh, V.; Ma, J.; Tardif, V.; Lim, R. K.; Pugh, H. M.; Sun, Y.; Manibusan, A.; Sellers, A. J.; Barnett, R. S.; Srinagesh, S.; Forsyth, J. S.; Hassenpflug, W.; Tian, F.; Javahishvili, T.; Felding-Habermann, B.; Lawson, B. R.; Kazane, S. A.; Schultz, P. G. *Angew. Chem., Int. Ed.* **2014**, 53 (44), 11863–7.
- (72) Hutchins, B. M.; Kazane, S. A.; Staflin, K.; Forsyth, J. S.; Felding-Habermann, B.; Schultz, P. G.; Smider, V. V. *J. Mol. Biol.* **2011**, 406 (4), 595–603.
- (73) Oller-Salvia, B.; Kym, G.; Chin, J. W. *Angew. Chem., Int. Ed.* **2018**, 57 (11), 2831–2834.
- (74) Nitta, S.; Numata, K. *Int. J. Mol. Sci.* **2013**, 14 (1), 1629–1654.
- (75) Hudson, D.; Margaritis, A. *Crit. Rev. Biotechnol.* **2014**, 34 (2), 161–179.